SCHEMBL2120145

SCHEMBL2120145

O=C(O)c1ccc(Cl)c(S(=O)(=O)N(Cc2ccccc2)c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 1.00
MEN1 O00255 9/20 1.00
POLB P06746 2/20 0.84
ALDH1A1 P00352 3/20 0.70
MITF O75030 1/20 0.64
RAD52 P43351 1/20 0.64
MAPT P10636 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
LMNA P02545 2/20 0.63
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.56
PTGES O14684 3/20 0.55
NSD2 O96028 1/20 0.55
ESR1 P03372 1/20 0.55
APEX1 P27695 1/20 0.55
RECQL P46063 1/20 0.55
ESR2 Q92731 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
ALOX5 P09917 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117559 0.94 KMT2A (1.00) KMT2AMEN1POLBALDH1A1MITF
SCHEMBL2119498 0.92 KMT2A (1.00) KMT2AMEN1POLBALDH1A1MITF
SCHEMBL2119250 0.89 MEN1 (1.00) KMT2AMEN1POLBALDH1A1MITF
SCHEMBL2119875 0.88 KMT2A (1.00) KMT2AMEN1POLBALDH1A1MITF
SCHEMBL11712969 0.83 KMT2A (0.71) KMT2AMEN1POLBALDH1A1MITF
SCHEMBL2121576 0.83 KMT2A (1.00) KMT2AMEN1POLBALDH1A1MITF
SCHEMBL3047865 0.78 PTGES (0.84) KMT2AMEN1ALDH1A1MAPTLMNA
SCHEMBL10250146 0.77 LMNA (1.00) KMT2AMEN1ALDH1A1MAPTLMNA
SCHEMBL2121606 0.77 KMT2A (1.00) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL2188004 0.76 ALDH1A1 (0.65) KMT2AMEN1POLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 KMT2A 941/4885MEN1 1593/4885POLB 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.